



Semimechanistic Pharmacokinetic and Pharmacodynamic Modeling of Piperaquine in a Volunteer Infection Study with *Plasmodium falciparum* Blood-Stage Malaria

Thanaporn Wattanakul,^a Mark Baker,^b  Joerg Mohrle,^c Brett McWhinney,^d Richard M. Hoglund,^{a,e} James S. McCarthy,^{f,g}  Joel Tarning^{a,e}

^aMahidol Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand

^bDepartment of Clinical Pharmacology, ViiV Healthcare, Geneva, Switzerland

^cMedicine for Malaria Venture, Meyrin, Switzerland

^dAnalytical Chemistry Unit, Pathology Queensland, Royal Brisbane and Women's Hospital, Brisbane, QLD, Australia

^eCentre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom

^fQIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia

^gSchool of Medicine, The University of Queensland, Brisbane, QLD, Australia

ABSTRACT Dihydroartemisinin-piperaquine is a recommended first-line artemisinin combination therapy for *Plasmodium falciparum* malaria. Piperaquine is also under consideration for other antimalarial combination therapies. The aim of this study was to develop a pharmacokinetic-pharmacodynamic model that might be useful when optimizing the use of piperaquine in new antimalarial combination therapies. The pharmacokinetic-pharmacodynamic model was developed using data from a previously reported dose-ranging study where 24 healthy volunteers were inoculated with 1,800 blood-stage *Plasmodium falciparum* parasites. All volunteers received a single oral dose of piperaquine (960 mg, 640 mg, or 480 mg) on day 7 or day 8 after parasite inoculation in separate cohorts. Parasite densities were measured by quantitative PCR (qPCR), and piperaquine levels were measured in plasma samples. We used nonlinear mixed-effect modeling to characterize the pharmacokinetic properties of piperaquine and the parasite dynamics associated with piperaquine exposure. The pharmacokinetics of piperaquine was described by a three-compartment disposition model. A semimechanistic parasite dynamics model was developed to explain the maturation of parasites, sequestration of mature parasites, synchronicity of infections, and multiplication of parasites, as seen in natural clinical infections with *P. falciparum* malaria. Piperaquine-associated parasite killing was estimated using a maximum effect (E_{\max}) function. Treatment simulations (i.e., 3-day oral dosing of dihydroartemisinin-piperaquine) indicated that to be able to combat multidrug-resistant infections, an ideal additional drug in a new antimalarial triple-combination therapy should have a parasite reduction ratio of $\geq 10^2$ per life cycle (38.8 h) with a duration of action of ≥ 2 weeks. The semimechanistic pharmacokinetic-pharmacodynamic model described here offers the potential to be a valuable tool for assessing and optimizing current and new antimalarial drug combination therapies containing piperaquine and the impact of these therapies on killing multidrug-resistant infections. (This study has been registered in the Australian and New Zealand Clinical Trials Registry under no. ANZCTR12613000565741.)

KEYWORDS antimalarial agents, pharmacokinetics, pharmacodynamics, population pharmacokinetics, pharmacology, piperaquine, *P. falciparum* malaria, controlled human malaria infection, induced blood-stage malaria

Dihydroartemisinin-piperaquine is one of the recommended first-line artemisinin-based combination therapies (ACTs) for uncomplicated *Plasmodium falciparum* malaria. In this antimalarial combination therapy, dihydroartemisinin serves as the

Citation Wattanakul T, Baker M, Mohrle J, McWhinney B, Hoglund RM, McCarthy JS, Tarning J. 2021. Semimechanistic pharmacokinetic and pharmacodynamic modeling of piperaquine in a volunteer infection study with *Plasmodium falciparum* blood-stage malaria. Antimicrob Agents Chemother 65:e01583-20. <https://doi.org/10.1128/AAC.01583-20>.

Copyright © 2021 Wattanakul et al. This is an open-access article distributed under the terms of the [Creative Commons Attribution 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

Address correspondence to Joel Tarning, joel@tropmedres.ac.

Received 7 August 2020

Returned for modification 17 September 2020

Accepted 10 January 2021

Accepted manuscript posted online 19 January 2021

Published 18 March 2021

rapid-acting component and piperazine as a long-acting partner drug. The ongoing emergence of resistance to both artemisinin and its partner drugs is threatening malaria control and eradication (1). The presence of resistance to artemisinin alone is considered a partial resistance because parasites remain sensitive to the partner drug, resulting in cure. However, in this circumstance, artemisinin resistance requires the partner drug to clear a higher residual parasite biomass, which risks the emergence of resistance to the partner drug. Therefore, artemisinin resistance contributes to the emergence of multidrug-resistant parasites and to increased rates of treatment failure.

Resistance to artemisinin derivatives has been reported in the Southeast Asia region, i.e., Cambodia, Lao People's Democratic Republic, Thailand, Myanmar, and Vietnam (1–3). Additionally, in 2016, a multisite prospective cohort study in Cambodia (4) demonstrated that patients with recrudescence presented with parasites with significantly decreased piperazine susceptibility compared with patients without recrudescence (mean piperazine 50% inhibitory concentration [IC₅₀], 64.0 versus 21.4 ng/ml; $P=0.0002$). In a separate study, a genome-wide association analysis of *Plasmodium falciparum* isolates from Cambodia demonstrated that amplification of genetic markers of piperazine resistance, such as *exo-E415G* SNP, *plasmepsin 2*, and *plasmepsin 3*, was significantly associated with decreased treatment efficacy (5). Therefore, artesunate plus mefloquine has been substituted as a new first-line ACT in some Cambodian provinces (5). To counteract the emergence of drug resistance, clinical trials have been undertaken (6) to assess the efficacy of triple ACTs, such as dihydroartemisinin-piperazine plus mefloquine, artemether-lumefantrine plus amodiaquine, and artemolane-piperazine plus mefloquine. Additionally, a combination of the novel ozonide antimalarial artefenomel with piperazine is under investigation (7).

Piperazine is a 4-aminoquinoline antimalarial drug whose clinical pharmacology is characterized by a long terminal elimination half-life (20 to 28 days) and a large between-patient variability in the pharmacokinetic profile in different subpopulations (8–11). Although its pharmacokinetic properties have been studied extensively, its pharmacodynamic properties in humans are less well studied, with available pharmacodynamic information (e.g., 50% effective concentration [EC₅₀]) being mostly extrapolated from *in vitro* data (5, 12, 13), which might not always represent the pharmacodynamic properties in humans. Pharmacodynamic models of piperazine in patients have been published previously in *Plasmodium vivax* malaria (14) and in chemoprevention of seasonal malaria (15). Knowledge of its key pharmacodynamic parameters in humans (e.g., EC₅₀) would provide information for improving current treatments using ACTs and assisting with dose selection in new antimalarial therapies (e.g., triple combinations).

The induced blood-stage malaria (IBSM) model has been extensively used to investigate the activity of antimalarial drugs in humans, including piperazine (16). In the IBSM model, healthy volunteers are inoculated with *P. falciparum*-infected erythrocytes, which allows for an evaluation of the activity of antimalarial drugs against the asexual blood stages of the parasites. Moreover, the IBSM model allows the investigation of parasite dynamics both before and after the antimalarial drug treatment, which is not possible with data from field studies where only parasite elimination can be studied.

The aim of this study was to develop a pharmacokinetic-pharmacodynamic model describing the parasite dynamics in healthy volunteers inoculated with blood-stage *P. falciparum* parasites using the IBSM model. The pharmacokinetic-pharmacodynamic model that was developed was then used to predict treatment failures in the presence of multidrug-resistant infections and characterize the ideal partner drug for triple-combination therapy for these infections.

RESULTS

Population pharmacokinetic model of piperazine. A total of 475 piperazine plasma concentrations were collected from 24 participants from 4 cohorts (Fig. 1). The characteristics of participants are shown in Table 1. Piperazine concentrations were measured to be above the lower limit of quantification in all plasma samples. The




FIG 1 Cohort diagram.

pharmacokinetic properties of piperaquine were best described by a three-compartment disposition model, characterizing the triphasic disposition of the drug (difference in objective function value [ΔOFV] = -41.3 ; 2 degrees of freedom [df], compared with two-compartment disposition model). An additional disposition compartment for piperaquine did not improve the model fit ($\Delta\text{OFV}=0$). The absorption process was best described by two-transit compartments, resulting in a substantial improvement compared with a traditional first-order absorption model ($\Delta\text{OFV} = -230$; 0 df). Interoccasion variability (IOV) was evaluated on absorption parameters, i.e., relative bioavailability (F) and mean absorption transit time (MTT), which improved the model fit significantly ($\Delta\text{OFV} = -37.8$; 2 df). An additive error model described the data accurately, and a combined additive and proportional error model did not improve the model fit ($\Delta\text{OFV}=0.05$). Implementation of body weight, using an allometric function, improved the model ($\Delta\text{OFV} = -4.44$; 0 df). No additional significant covariates were found during the stepwise covariate search. The model evaluations indicated satisfactory results, with no obvious trends in the goodness of fit plots (see Fig. S1A to D in the supplemental material). Similarly, the visual predictive check (Fig. S1E) demonstrated a good predictive performance of the model. The numerical predictive check ($n=2,000$) showed that 3.2% (95% confidence interval [CI], 1.5% to 10.1%) of piperaquine observations were below the simulated 90% prediction interval and 5.1% (95% CI, 1.3% to 9.9%) were above. The bootstrap results demonstrated acceptable robustness of the piperaquine population pharmacokinetic model. The final pharmacokinetic parameter estimates of piperaquine, with precision and shrinkage are summarized in Table 2.

***P. falciparum* parasite growth model.** A recently published pooled analysis of parasite growth data from malaria volunteer infection studies, using a larger data set including results from this study, reported a parasite life cycle of 38.8 h (17). Thus, the parasite life cycle was fixed to 38.8 h in all growth models evaluated in the current study. A total of 8.82% of the observed parasite density values were below the lower limit of detection (LOD), and these data were successfully handled using the M3 method (15). Three parasite growth models were evaluated, as described below.

Log-linear growth model and sine-wave growth model. The parasite growth rate (k_G) estimated from a log-linear growth model was 0.066 h^{-1} , equivalent to a parasite multiplication rate per life cycle (PMR_{LC} ; parasite multiplication rate, equivalent to the number of new merozoites released from 1 schizont) of 12.9-fold (95% CI, 11.5 to 14.3). Adding interindividual variability on parasite life cycle improved the model fit ($\Delta\text{OFV} = -6.29$; 1 df). Additional interindividual variability on k_G did not improve the model fit

TABLE 1 Participant characteristics

Characteristic	Values
Age (yrs) ^a	22.5 (18–32)
BMI ^b (kg/m ²) ^a	22.8 (18.3–27.9)
Height (cm) ^a	173 (149–186)
Weight (kg) ^a	69.3 (51.1–86.9)
Sex ^c	
Male	15 (62.5)
Female	9 (37.5)
Race ^c	
Australian White	20 (83.3)
Australian Asian	1 (4.17)
Other	3 (12.5)

^aValues are median (range).^bBMI, body mass index.^cValues are *n* (%).

further ($\Delta\text{OFV} = 0.002$; 1 df). For the sine-wave growth model, k_G was estimated at 0.065 h^{-1} , equivalent to PMR_{LC} of 12.6-fold (95% CI, 11.1 to 14.0). The sine-wave growth model improved the model fit compared with the log-linear model ($\Delta\text{OFV} = -69.7$; difference in Bayesian information criterion [ΔBIC] = -59.5). Adding interindividual variability on k_G improved the model fit ($\Delta\text{OFV} = -20.0$; 1 df). Additional interindividual variability on parasite life cycle did not improve the model fit further ($\Delta\text{OFV} = 0.03$; 1 df). The final parameter estimates of the log-linear growth model and the sine-wave growth model are summarized in Table S1 and S2, respectively, in the supplemental material. The goodness of fit of the growth phase data using log-linear and sine-wave growth models showed an acceptable overall goodness of fit with no obvious systematic model misspecifications (see Fig. S2 in the supplemental material).

Semimechanistic growth model. A semimechanistic growth model mimicking the natural *P. falciparum* malaria parasite life cycle was developed. The rate constant of parasite maturation (k_{MAT}) and the rate constant of schizont rupture (k_{RUP}) were fixed to an arbitrary high value of 2 in order to ensure that all parasites matured from being young rings to mature parasites and that schizont rupture took place at 38.8 h (resulting in parasite multiplication). The fraction of parasite sequestration (F_{SQ}) was not identifiable with the data available. A sensitivity analysis of F_{SQ} was performed by fixing this parameter, ranging from 40% to 90% with a 10% increase each time. No alteration was observed in the OFV or in model goodness-of-fit diagnostics, suggesting identifiability issues of F_{SQ} . However, the observed growth phase data showed a recurring 10-fold

TABLE 2 Population pharmacokinetic parameter estimates from the final pharmacokinetic model of piperazine

Parameter ^a	Population estimate ^b (% RSE) ^c	Population estimate ^b 95% CI ^c	IIV ^b or IOV ^b (% RSE) ^c	IIV ^b or IOV ^b 95% CI ^c	Shrinkage (%)
F	1 Fixed		43.7 (14.4), 19.0 (28.8) ^d	28.1–56.0, 5.98–29.1 ^d	6.22, 64.2 ^d
MTT (h)	3.05 (5.44)	2.66–3.31	39.4 (29.7) ^d	12.3–64.5 ^d	45.0 ^d
CL/F (liter/h)	52.4 (10.4)	42.2–63.4	39.2 (17.2)	22.6–50.8	15.3
V_c /F (liter)	542 (22.1)	349–842			
Q_1 /F (liter/h)	2,400 (41.1)	1,210–4,670	298 (18.7)	121–695	12.1
V_{p1} /F (liter)	3,320 (12.7)	2,580–4,220	27.4 (34.0)	1.74–45.2	29.4
Q_2 /F (liter/h)	152 (12.3)	122–196	20.7 (43.5)	0.561–38.1	53.3
V_{p2} /F (liter)	13,500 (13.0)	10,500–17,300	18.8 (40.1)	0.412–30.4	51.4
σ	0.114 (5.04)	0.091–0.134			10.0

^aF, relative bioavailability; MTT, mean transit time; CL/F, apparent oral clearance; V_c /F, apparent central volume of distribution; Q_1 /F, apparent intercompartmental clearance from central compartment to peripheral compartment; V_{p1} /F, apparent peripheral volume of distribution; and σ , residual unexplained variability.

^bPopulation mean parameters estimated from NONMEM, based on a typical individual weighing 69.3 kg. Interindividual variability (IIV) and interoccasion variability (IOV) are presented as the coefficient of variation (% CV), calculated as $100 \times \sqrt{\exp(\text{estimate}) - 1}$.

^cBased on nonparametric bootstrap diagnostics ($n = 1,000$). Parameter precision is presented as relative standard deviation (% RSE), calculated as $100 \times \text{standard deviation} / \text{mean value}$.

^dValues for interoccasion variability.

TABLE 3 Population pharmacodynamic model parameter estimates

Parameter ^a	Population estimate ^b (% RSE) ^c	Population estimate ^b 95% CI ^c	IIV ^b (% RSE) ^c	IIV ^b 95% CI ^c	Shrinkage (%)
Semimechanistic growth model					
P1 (h)	0–9.7 Fixed				
P2 (h)	9.7– T_{PC} Fixed				
P3 (h)	T_{SQ} – T_{PC} Fixed				
F_{SUR} (%)	5 Fixed				
T_{PC} (h)	38.8 Fixed		6.00 (24.8)	5.11–8.50	34.5
k_{MAT} (h^{-1})	2 Fixed				
T_{SQ} (h)	29.1 (4.84)	27.7–29.7			
F_{SQ} (%)	90 Fixed				
k_{RUP} (h^{-1})	2 Fixed				
PMR_{LC}	15.7 (8.43)	14.1–19.9	18.3 (27.7)	15.4–33.3	14.6
<i>In vivo</i> parasitocidal effect of piperaquine					
E_{max} (h^{-1})	0.289 (5.31)	0.262–0.321	23.6 (26.0)	5.20–30.0	18.7
EC_{50} (ng/ml)	5.43 (29.4)	1.77–7.33	114 (38.6)	67.0–760	30.6
γ	2.8 Fixed				
σ	4.69 (4.80)	3.81–5.55			7.69

^aP1, age of circulating small rings; P2, age of circulating large rings, trophozoites and schizonts; P3, age of sequestered trophozoites and schizonts; F_{SUR} , fraction of parasite survival after inoculation; T_{PC} , duration of parasite life cycle; k_{MAT} , first-order rate constant for parasite maturation; T_{SQ} , onset of parasite sequestration; F_{SQ} , fraction of parasites sequestration; k_{RUP} , first-order rate constant of schizont rupture; PMR_{LC} , parasite multiplication rate given as fold increase per life cycle; E_{max} , maximum parasite killing rate of piperaquine; C_p , piperaquine plasma concentration; EC_{50} , plasma concentration of piperaquine associated with half of maximum parasite killing rate; γ , hill factor; and σ , residual unexplained variability.

^bPopulation mean parameters estimated from NONMEM, based on a typical individual weighting 69.3 kg. Interindividual variability (IIV) and interoccasion variability (IOV) are presented as the coefficient of variation (% CV), calculated as $100 \times \sqrt{\exp(\text{estimate}) - 1}$.

^cBased on nonparametric bootstrap diagnostics ($n = 1,000$). Parameter precision is presented as relative standard deviation (% RSE), calculated as $100 \times \text{standard deviation} / \text{mean value}$.

drop in total circulating parasites (P_{CIR}), suggesting that the fraction of parasite sequestration should be approximately 90%. Thus, the F_{SQ} was fixed to 90% according to these observations. The onset of sequestration (T_{SQ}) was estimated at 29.1 h (95% CI, 27.7 to 29.7 h). Parasite growth rate was estimated as 0.0710 h^{-1} (95% CI, 0.0682 to 0.0771 h^{-1}), equivalent to a PMR_{LC} of 15.7-fold (95% CI, 14.1 to 19.9). Adding interindividual variability on the parasite life cycle and PMR_{LC} improved the model fit ($\Delta OFV = -48.6$; 2 df).

The developed semimechanistic growth model described the observed data well and the goodness of fit of the semimechanistic growth model demonstrated a better model fit than the log-linear growth model ($\Delta OFV = -33.2$, $\Delta BIC = -22.9$) and also in terms of describing the net decrease in total circulating parasite number, a consequence of parasite sequestration (Fig. S2). The semimechanistic growth model did not result in a better model fit, in terms of ΔOFV and ΔBIC , compared with the sine-wave growth model ($\Delta OFV = 36.5$, $\Delta BIC = 36.5$), but demonstrated a similar goodness of fit. However, the semimechanistic growth model gave some advantages by describing the maturation of parasites, sequestration of mature parasites, synchronicity of infections (i.e., synchronous parasite maturation and multiplication resulting in periodic bursts of red blood cells and the release of young parasites), and multiplication of parasites, as described in natural infections with *P. falciparum*. These advantages provided additional flexibility for investigating drug effects on specific stages of the parasite life cycle. Thus, the semimechanistic growth model was carried forward for further investigation. The final parameter estimates with precision and shrinkage of model parameters are presented in Table 3.

***In vivo* parasitocidal effect of piperaquine.** The pharmacokinetic-pharmacodynamic model was developed to investigate the *in vivo* parasitocidal effect of piperaquine. The schematic of the final pharmacokinetic-pharmacodynamic model is shown in Fig. 2. The parasitocidal effect of piperaquine (EFF) was added as a direct effect (equations 14 and 15 in Materials and Methods) to the mature parasite compartments (P2 and P3), describing the drug-dependent parasite elimination adequately. The model estimated the maximum parasite killing rate of piperaquine (E_{max}) as 0.289 h^{-1} (95% CI, 0.262 to 0.323 h^{-1}) with an estimated EC_{50} of 5.43 ng/ml (95% CI, 1.68 to




FIG 2 The schematic of final pharmacokinetic-pharmacodynamic model describing the semimechanistic model of *P. falciparum* malaria parasites and the final pharmacokinetic model of piperaquine. In the piperaquine pharmacokinetic model (left), F represents relative bioavailability, k_{tr} represents transit rate constant, CL/F represents apparent oral clearance, V_c/F represents apparent central volume of distribution (PK sampling compartment), Q/F represents intercompartmental clearance from central compartment to peripheral compartment, and V_p/F represents apparent peripheral volume of distribution. In the parasite dynamic model (right), circulating parasites (P1 + P2) represent the observed parasitemia, k_{MAT} represents first-order rate constant of parasite maturation, k_{SQ} represents first-order rate constant of parasite sequestration, and k_{RUP} represents first-order rate constant of schizont rupture. The killing effect of piperaquine (EFF) was described by an E_{max} function; E_{max} represents the maximum parasite killing rate of piperaquine, C_p represents piperaquine plasma concentration, and EC_{50} represents plasma concentration of piperaquine associated with half of maximum parasite killing rate.

7.33 ng/ml), resulting in a median parasite reduction ratio per life cycle (PRR_{LC}) of 2.68×10^2 , 2.89×10^2 , and 3.02×10^2 when piperaquine was given as a single dose of 480, 640, and 960 mg piperaquine phosphate, respectively. The median minimum inhibitory concentration (MIC) of piperaquine derived from the 24 healthy volunteers was 2.87 ng/ml (95% CI, 1.87 to 18.3 ng/ml). The goodness-of-fit diagnostics of the final pharmacokinetic-pharmacodynamic model are presented in Fig. S3 in the supplemental material, simulation-based diagnostics (i.e., visual predictive checks) are presented in Fig. 3, and individual plots of the final pharmacokinetic-pharmacodynamic model are presented in Fig. S4 in the supplemental material. Parameter estimates from the final pharmacokinetic-pharmacodynamic model are presented in Table 3.

Simulations of clinical scenarios. In order to simulate treatment scenarios of drug-resistant infections, dihydroartemisinin was used as a representative artemisinin derivative. The parasitocidal effect of dihydroartemisinin was adjusted based on the observed parasite clearance half-life from the Tracking Resistance to Artemisinin Collaboration (TRAC) study data (18). The adjusted dihydroartemisinin E_{max} values were 0.477 h^{-1} and 0.216 h^{-1} for sensitive and resistant infections, respectively (see Fig. S5 in the supplemental material).

Various degrees of piperaquine resistance were represented by doubling (10.9 ng/ml), tripling (16.3 ng/ml), and quadrupling (21.7 ng/ml) the estimated EC_{50} of sensitive parasites (5.43 ng/ml). In a symptomatic infection (initial total circulating parasites of 10^{10}), these simulations predicted a similar probability of treatment failure in piperaquine resistance alone compared with dihydroartemisinin resistance alone (2.58% versus 1.81%). The probability of treatment failure increased with multidrug-resistant infections, resulting in 23.6% treatment failures in the presence of dihydroartemisinin resistance and a high-degree of piperaquine resistance (EC_{50} of 21.7 ng/ml). A similar trend of treatment failure was predicted in asymptomatic infections (initial total circulating parasites of 10^6). A summary of the treatment failure probability of each drug-




FIG 3 The simulated 90% prediction interval from the final pharmacokinetic-pharmacodynamic model ($n=1,000$). The open circles represent the observed total circulating parasites. Solid red lines represent the 50th percentiles of the observations, and horizontal black lines represent the lower limit of parasite detection (LOD). The shaded areas represent the 90% prediction intervals of the simulation.

resistant scenario is presented in Table 4. Additionally, simulations to inform on suitable pharmacokinetic-pharmacodynamic characteristics for candidate partner drugs used in triple-combination therapy demonstrated that the addition of a hypothetical drug with a PRR_{LC} of $\geq 10^2$ and total therapeutic duration of ≥ 2 weeks had a $>99\%$ probability of successful treatment. The summary of treatment failure probability with simulated hypothetical partner drug activities against multidrug-resistant infections is presented in Table 5.

DISCUSSION

In the present study, a semimechanistic growth model describing *P. falciparum* parasite dynamics was successfully developed. The integration of piperaquine pharmacokinetics and parasite dynamics using data from a study conducted using the IBSM model allowed the estimation of the *in vivo* pharmacodynamic parameters of piperaquine.

The PMR_{LC} estimated from the log-linear growth model (12.9; 95% CI, 11.5 to 14.3), the sine-wave growth model (12.6; 95% CI, 11.1 to 14.0), and the semimechanistic growth model (15.7; 95% CI, 14.1 to 19.9) were all similar to those reported in a pooled analysis of growth data (16.4; 95% CI, 15.1 to 17.8) (17) and were also similar to the approximately 10-fold multiplication rate reported in natural infections (19, 20). During parasite growth model development, the log-linear and cosine-wave models estimated F_{SUR} as less than 1% with high relative standard errors of 57% and 41%, respectively.

TABLE 4 Predicted probability of treatment failure associated with different levels of drug resistance

Drug-resistant scenario ^a	Probability of treatment failure (%)	
	Asymptomatic infection ^b	Symptomatic infection ^c
DHA sensitive ($E_{\max} = 0.477$), PQ sensitive ($EC_{50} = 5.4$ ng/ml)	<1.00	<1.00
DHA resistant ($E_{\max} = 0.216$), PQ sensitive ($EC_{50} = 5.4$ ng/ml)	<1.00	1.81
DHA sensitive ($E_{\max} = 0.477$), PQ resistant ($EC_{50} = 10.9$ ng/ml)	<1.00	2.58
DHA resistant ($E_{\max} = 0.216$), PQ resistant ($EC_{50} = 10.9$ ng/ml)	2.44	8.06
DHA resistant ($E_{\max} = 0.216$), PQ resistant ($EC_{50} = 16.3$ ng/ml)	7.10	15.2
DHA resistant ($E_{\max} = 0.216$), PQ resistant ($EC_{50} = 21.7$ ng/ml)	10.6	23.6

^aDHA, dihydroartemisinin; PQ, piperaquine; E_{\max} , maximum parasite killing rate of dihydroartemisinin; and EC_{50} , concentration of piperaquine associated with half of maximum parasite killing rate.

^bInitial total circulating parasites for asymptomatic infection of 10^6 parasites.

^cInitial total circulating parasites for symptomatic infection of 10^{10} parasites.

The semimechanistic growth model estimated F_{SUR} as 5.4% with a relative standard error of 19%. Pooling data from several studies conducted at QIMR Berghofer Medical Research Institute (QIMR), a separate pharmacokinetic/pharmacodynamic model estimated the fraction of survival for inoculated parasites as 5%. In order to avoid bias when comparing parasite growth models and the difficulties in estimating this parameter from the available data, F_{SUR} was fixed to 5% based on our semimechanistic growth model and the unpublished model from QIMR.

In the semimechanistic growth model, the mean starting time point of parasite sequestration was estimated at 29.1 h. Sequestration is not likely to start at the same time in all individuals, but the estimated interindividual variability in this parameter was large with low precision. This result is most likely due to the limited number of measurements of parasitemia across the parasite life cycle. Thus, interindividual variability was retained only in the length of the parasite life cycle and parasite multiplication rate in the final semimechanistic growth model.

The parasitocidal effect of piperaquine on *P. falciparum* predominantly affects late-stage parasites (trophozoites and schizonts) (18, 21, 22). Therefore, the parasitocidal effect of piperaquine was assumed to be against only the late-stage parasites in the semimechanistic growth model, both in peripheral circulation and in the sequestered vascular compartment. The goodness of fits and individual fits demonstrated that the developed model described the observed data adequately both in recrudescence and nonrecrudescence individuals. Simulation-based diagnostics of the final pharmacokinetic-pharmacodynamic model demonstrated a good predictive performance of cured individuals, but the simulated prediction intervals of individuals with recrudescence showed relatively large variability. This finding could be explained by the small proportion of recrudescence data available in this study.

The estimated *in vivo* EC_{50} of 5.43 ng/ml (95% CI, 1.68 to 7.33 ng/ml) was similar to the mean IC_{50} values of piperaquine against the 3D7 parasite strain, which was reported in two *in vitro* susceptibility studies (1.69 to 7.34 ng/ml) (23, 24). However, this estimated *in vivo* EC_{50} was lower than the *in vitro* IC_{50} value reported for sensitive infections in the field. The *in vitro* IC_{50} of piperaquine reported in 2011 in three sites in Cambodia were 10.7 ng/ml (interquartile range [IQR], 7.34 to 15.5 ng/ml) in Ratanakiri, 10.3 ng/ml (IQR, 8.09 to 14.0 ng/ml) in Preah Vihear, and 10.5 ng/ml (IQR, 6.37 to 18.2 ng/ml) in Pursat (5). The lower estimated EC_{50} in this study than IC_{50} values reported in the field might be partially explained by the different genetic background of the parasites, i.e., the 3D7 strain used in the current study was originally isolated from Africa and is sensitive to chloroquine and several antimalarial drugs, including piperaquine (23–25). The median PRR_{LC} derived from the final pharmacodynamic model was 2.68×10^2 to 3.02×10^2 at standard therapeutic doses. These values are similar to the

TABLE 5 Predicted probability of treatment failure associated with treating a symptomatic infection with hypothetical triple combination therapy^a

Drug-resistant scenario	Probability of treatment failure (%)						
	DHA + PQ ^b	PRR _{LC}	Hypothetical drug characteristics				
			Duration of action (wks)				
			1	2	3	4	5
DHA resistant ($E_{\max} = 0.216$), PQ resistant ($2 \times EC_{50} = 10.9$ ng/ml)	8.1	10^1	4.19	2.79	2.27	2.29	2.23
		10^2	1.42	<1.00	<1.00	<1.00	<1.00
		10^3	<1.00	<1.00	<1.00	<1.00	<1.00
DHA resistant ($E_{\max} = 0.216$), PQ resistant ($3 \times EC_{50} = 16.3$ ng/ml)	15.2	10^1	9.35	5.60	5.31	5.46	5.46
		10^2	3.65	<1.00	<1.00	<1.00	<1.00
		10^3	<1.00	<1.00	<1.00	<1.00	<1.00
DHA resistant ($E_{\max} = 0.216$), PQ resistant ($4 \times EC_{50} = 21.7$ ng/ml)	23.6	10^1	15.3	10.7	10.0	9.96	9.94
		10^2	6.02	<1.00	<1.00	<1.00	<1.00
		10^3	1.25	<1.00	<1.00	<1.00	<1.00

^aThe hypothetical drug was added to the standard 3-day dose of DHA-PQ (120/960 mg). DHA, dihydroartemisinin; PQ, piperaquine; E_{\max} , maximum parasite killing rate of dihydroartemisinin; EC_{50} , concentration of piperaquine associated with half of maximum parasite killing rate; and PRR_{LC}, parasite reduction ratio per parasite life cycle (38.8 h).

^bInitial total parasite biomass for symptomatic infection of 10^{10} parasites.

48-h parasite reduction ratio (PRR_{48h}) of 10^2 to 10^5 reported in the literature (26, 27), which correspond to a PRR_{LC} of approximately 4.14×10^1 to 1.10×10^4 when corrected for a shorter life cycle length. However, the reduction ratio reported in the present study is in the lower end of what has been reported in the literature. This difference can be explained by several factors such as the synchronicity of the infection, potential differences between the laboratory strain used in this model and clinical isolates (e.g., parasite life cycle, parasite multiplication rate, and parasite susceptibility to piperaquine), and the difference in background immunity in malaria-naïve volunteers versus patients from regions of malaria endemicity with pre-exposure to malaria.

Simulations of multidrug-resistant scenarios predicted a probability of treatment failure that was somewhat lower than that reported in the clinical settings in Cambodia, especially in the scenario with an extremely resistant infection (i.e., 4-fold increase in EC_{50} as reported in Pursat). The rates of clinical recrudescence reported from this study in 2013 were 2%, 16%, and 46% in Ratanakiri, Preah Vihear, and Pursat, respectively. The *in vitro* IC_{50} of piperaquine in these 3 study sites was increased by approximately 2-, 3-, and 4-fold, respectively, in 2013 compared with the values reported in 2011 (4, 5). Assuming the same increase in EC_{50} in the present study resulted in simulated failure rates of 8.1%, 15.2%, and 23.6%. The difference in the predicted proportion of treatment failures versus observed clinical failure rates could possibly be a result of a difference in parasite dynamics as discussed above and/or the pharmacokinetic properties of piperaquine, which might differ between healthy volunteers and patients. Differences in treatment adherence could also partly explain the difference. Moreover, the assumption of the model with respect to the dihydroartemisinin parasite killing effect (E_{\max}), based on the parasite clearance half-life values associated with artesunate in sensitive and resistant infections from a previous study (28), might not be a perfect representation of dihydroartemisinin resistance occurring in the field. The simulations in the current study enabled a prediction of the probability of treatment failure when an additional partner drug was added to the conventional dihydroartemisinin-piperaquine regimen. This information could help with the selection of new combination therapies and optimization of dosing regimens. In all simulations of treatment failures, an additive drug effect was assumed for drugs included in the treatment. We believe this is the most conservative approach, considering the limited information available on drug synergisms/antagonisms of antimalarial drugs. However, applying a different drug interaction could yield different results. A previous study (29) showed that a model incorporating a different magnitude of interactions between antimalarial drugs, using dihydroartemisinin-piperaquine plus mefloquine as

an example, predicted a reduced probability of treatment cure when the level of antagonism between piperazine and mefloquine was high.

Some limitations of the semimechanistic model developed in the current study include characterization of the fraction of sequestered parasite (F_{SQ}) and the relatively high uncertainty in estimation of the time to sequestration. These issues could be overcome by more frequent measurements of parasite densities during the growth phase. Furthermore, stage-specific parasite measurements could also enhance the robustness and reliability of the model. The semimechanistic growth model resulted in improved model fit compared with the log-linear model but did not result in a better model fits, in terms of ΔOFV and ΔBIC , compared with the sine-wave growth model. Nevertheless, we believe that a semimechanistic growth model, based on observed biological processes in the parasite life cycle, is preferable to an empirical description of the data and a more useful tool for translational simulations, especially since the developed semimechanistic model can be modified to include antimalarial drugs with different mechanisms of action (i.e., drug effect can be incorporated at different stages in the parasite life cycle depending on the mechanism of action). Another limitation is the potential differences between the *P. falciparum* strain used in the IBSM model (3D7) and those in patients with clinical malaria. If the *P. falciparum* strain used in the IBSM model is more drug susceptible than the strains in clinical infections, this would lead to an overestimation of the drug-mediated killing of parasites. However, the pharmacokinetic-pharmacodynamic model structure, incorporating a semimechanistic growth model, allows the flexibility to evaluate drug effects to a specific stage of the parasite life cycle. Furthermore, the model explained the processes described in natural *P. falciparum* malaria infections, including maturation of parasites, sequestration of mature parasites, synchronicity of infections, and multiplication of parasites. The implementation of this model structure to growth phase data from a large pool of malaria volunteer infection studies could further confirm the robustness of the model and hopefully allow for all model parameters to be estimated.

In conclusion, an *in vivo* semimechanistic model of parasite growth and clearance was developed in participants inoculated with *P. falciparum* malaria, and model parameters (E_{max} , EC_{50} , and PRR_{LC}) associated with piperazine pharmacokinetic-pharmacodynamic effects were estimated. This semimechanistic parasite model provides important insights and could be an important tool in the development of novel triple-combination therapies and for dose optimization of piperazine and other antimalarial drugs.

MATERIALS AND METHODS

Study design. Pharmacokinetic and pharmacodynamic data were collected from 24 healthy volunteers who participated in a previously described phase-Ib single-center clinical trial (26). In brief, the study was conducted at the contract research organization Q-Pharm (Brisbane, Australia). Malaria-naïve subjects aged 18 to 50 years old who met all of the inclusion and none of the exclusion criteria were eligible to enroll in the study. The study protocol was approved by the QIMR Berghofer Human Research Ethics Committee and was registered in the Australian and New Zealand Clinical Trials Registry (ANZCTR12613000565741). Eligible participants were intravenously inoculated with approximately 1,800 viable *P. falciparum*-infected human erythrocytes (chloroquine-susceptible 3D7 strain) on day 0. A single dose of piperazine was given to participants in four different cohorts. The doses of piperazine phosphate were 960 mg (cohort 1), 640 mg (cohort 2), and 480 mg (cohorts 3a and 3b). Piperazine was administered on day 7 (cohort 1 and 3b; $n = 11$) or day 8 (cohort 2 and 3a; $n = 13$) after inoculation. The parasite density in inoculated participants was quantified using a quantitative PCR (qPCR) that targets the *P. falciparum* 18S rRNA gene (30). Treatment for malaria recrudescence consisted of artemether-lumefantrine in cohorts 1 and 2 and a second dose of piperazine (960 mg) in cohorts 3a and 3b. At the end of the study, artemether-lumefantrine was given to all participants as a curative malaria treatment. Plasma concentrations of piperazine were measured using liquid chromatography and mass spectrometry. The plasma samples were collected before piperazine administration; at 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, and 144 hours after piperazine administration; at 8, 11, and 14 days after treatment; and at the end of study (day 28 for cohorts 1 and 2, day 37 for cohort 3a, and day 35 for cohort 3b). For cohorts 3a and 3b, an additional sample was taken 18 days after piperazine administration. The range of the assay was 0.5 to 1000 $\mu\text{g/liter}$ for piperazine. The coefficient of variation across four different concentration levels was 1.2% to 4.4% ($n = 10$) for the intraassay and 2.5% to 6.6% ($n = 10$) for the interassay comparisons. The accuracy of the assay was 97% to 104% ($n = 10$).

Pharmacometric analysis. The population pharmacokinetic and pharmacodynamic analysis was performed using nonlinear mixed-effects modeling in NONMEM, version 7.4 (Icon Development Solution, Ellicott City, MD). RStudio version 1.2.1335 (31), Xpose version 4.0, Pirana version 2.9.4 (32), and

Pearl-speaks-NONMEM (PsN) version 4.7.0 (33) were used for model diagnostics and visualization of results. Piperaquine base plasma concentrations were transformed into their natural logarithms prior to pharmacokinetic model development. None of the samples had piperaquine concentrations measured below the lower limit of quantification. The first-order conditional estimation method with interaction (FOCE-I) was used throughout the pharmacokinetic model building process. The average parasite density from qPCR measurements (parasites/ml) was transformed into the total circulating parasites (P_{CIR} ; parasites) prior to pharmacodynamic model development (equation 2). The calculated total circulating parasite densities were transformed into their natural logarithms prior to pharmacodynamic model development. qPCR measurements below LOD (1 parasite/ml) were treated as categorical data and were modeled simultaneously with the reported continuous parasite density data above LOD, using the M3 method (34). Pharmacodynamic parameters were estimated using the FOCE-I and the Laplacian method (35). The difference in objective function value (ΔOFV) was used as a statistical criterion for discrimination between nested models. The difference in Bayesian information criterion (ΔBIC) was used when comparing nonnested models (36).

The descriptive performance of the model was assessed by goodness-of-fit diagnostics, and the predictive performance of the model was evaluated by simulation-based diagnostics. Eta and epsilon shrinkages were used to evaluate the reliability of the individual estimates and the ability to detect model misspecification in the goodness-of-fit diagnostics (37). The predictive performance of the final model was illustrated by visual and numerical predictive checks ($n = 2,000$). The 5th, 50th, and 95th percentile of the observed concentrations was overlaid with the 95% CI of each simulated percentile to detect model bias. Model robustness and nonparametric CI were evaluated using a bootstrap methodology ($n = 1,000$).

Population pharmacokinetic model of piperaquine. Pharmacokinetic parameters were assumed to be log-normally distributed, and interindividual variability was therefore implemented with an exponential function. Interoccasion variability, also implemented with an exponential function, was investigated to reflect the random variability between dosing occasions. An additive error model and a combined additive and proportional error model, both on the logarithmic scale, were evaluated. To evaluate the effect of body size on the pharmacokinetic properties of piperaquine, body weight was implemented as an allometric function on all clearance and volume of distribution parameters (equation 1).

$$\theta_i = \theta \times e^{\eta_{i,\theta}} \times \left(\frac{BW_i}{BW_{\text{median}}} \right)^n \quad (1)$$

where θ_i denotes individual clearance or individual volume of distribution parameter, θ denotes the typical value (population mean) of clearance or volume parameters, BW_i denotes individual body weight, BW_{median} denotes median body weight of the participants, and n was set to be equal to 0.75 for clearance parameters and 1 for volume parameters. Additional covariate relationships including age, sex, and race were examined using a stepwise forward inclusion ($P < 0.05$, $\Delta\text{OFV} = -3.84$), followed by stepwise backward elimination ($P > 0.001$, $\Delta\text{OFV} = -10.83$) procedure.

***P. falciparum* parasite growth model.** The initial total number of circulating parasites (P_{CIR}) was fixed to 1,800 parasites (equivalent to the approximate number of viable inoculated parasites) for all investigated parasite growth models, and the fraction of parasite survival (F_{SUR}) after inoculation was fixed to 5%, based on results from a pharmacokinetic/pharmacodynamic model using pooled induced blood-stage malaria data at QIMR (unpublished work). The parasite life cycle was fixed to 38.8 h (17). The average parasite density from qPCR measurements (parasites/ml) at each time point was transformed to the P_{CIR} based on individual body weight multiplied by the average blood volume which was assumed to be 80 ml/kg (equation 2) (38).

$$P_{\text{CIR}} = \text{average parasite density (parasites/ml)} \times \text{body weight (kg)} \times 80 \text{ (ml/kg)} \quad (2)$$

The calculated number of total circulating parasites was transformed into natural logarithms for parasite dynamic model development. Initially, only the growth-phase data were used to develop the parasite growth model (Fig. S6). Three different types of models were evaluated, namely, log-linear growth model, sine-wave growth model, and a semimechanistic growth model. The parasite dynamic model that best described the observed data was carried forward to evaluate parasite dynamics after piperaquine administration. The details of each parasite growth model are described below.

Log-linear growth model and sine-wave growth model. The log-linear growth model used to describe parasite growth data was implemented using a differential equation to explain the change of parasite density with time (equation 3).

$$\frac{dP_{\text{CIR}}}{dt} = P_{\text{CIR}} \times k_G \quad (3)$$

where P_{CIR} denotes the number of total circulating parasites (parasites) and k_G denotes parasite growth rate (h^{-1}). The sine-wave model used in the previously published pooled analysis of parasite growth data from volunteer infection studies (17) was implemented to describe parasite growth data in the current study (equation 4).




FIG 4 Semimechanistic growth model describing *P. falciparum* parasite dynamics. The left panel demonstrates the structure of the parasite growth model; (P1) represents small ring parasites that are circulating in the peripheral blood; (P2) represents the large rings, trophozoites, and schizonts that are circulating in the blood; (P3) represents the matured sequestered parasites; k_{MAT} represents first-order rate constant of parasite maturation [$REG1 \times 2$ (fixed)]; k_{SQ} represents first-order rate constant of parasite sequestration [$REG2 \times k_{SQ}$]; and k_{RUP} represents first-order rate constant of schizont rupture [$REG3 \times 2$ (fixed)]. The right panel demonstrated the sine-wave function used to regulate the parasite dynamics in each compartment and the associated parasite number at each stage of parasite life cycle. The equations used to generate the sine-wave function are presented in the supplemental material (NONMEM code).

$$\ln(P_{CIR}) = a + k_G \times \text{time} + C \times \sin \left[\left(\frac{2 \times \pi}{T_{PC}} \right) \times \text{time} + k \right] \quad (4)$$

where, $\ln(P_{CIR})$ denotes the natural logarithm of total circulating parasites (parasites), a denotes y-intercept (i.e., the P_{CIR} at time zero), time denotes time after parasite inoculation (h), C denotes sine-wave amplitude, T_{PC} denotes duration of the parasite life cycle (fixed to 38.8 h), and k denotes sine-wave phase shift. The overall parasite multiplication rate per life cycle (PMR_{LC}) from the log-linear growth and sine-wave growth model was calculated using the estimated parasite growth rate and the duration of the parasite life cycle (equation 5).

$$PMR_{LC} = e^{(T_{PC} \times k_G)} \quad (5)$$

Semimechanistic growth model. The semimechanistic model was developed based on prior knowledge of the *P. falciparum* life cycle. Time windows corresponding to *P. falciparum* parasite stages were based on the microscopic observations previously reported (39). These time windows were corrected for a shorter life cycle length used in the current study (38.8 h). The proposed model consisted of three parasite compartments (Fig. 4). The first parasite compartment (P1) represents the small rings that are circulating in the peripheral blood. The second parasite compartment (P2) represents the large rings, trophozoites, and schizonts that are also circulating in the blood. These two parasite compartments represent the total circulating parasites in the peripheral blood, which can be measured by qPCR and microscopy.

However, the total parasite biomass also includes sequestered parasites, which attach to endothelial cells. The third parasite compartment (P3) represents the sequestered parasites. Thus, combining the parasite number in all parasite compartments (P1, P2, and P3) yields a total parasite biomass in the body.

Three square-wave functions were used to regulate the movement of the parasites between each compartment at specific time periods (REG_1 , REG_2 , and REG_3). These square-wave functions were set to change from 0 to 1 (i.e., "on-and-off") during certain time periods to move parasites between the different parasite compartments. These square-wave functions were described by the following equations (equation 6 to 8).

$$S_1 = \sin \left\{ \frac{\left[\pi - \left(\frac{2\pi \times SH_1}{T_{PC}} \right) \right]}{2} \right\} \quad (6)$$

$$S_2 = \sin \left\{ \left(\frac{2\pi \times \text{time}}{T_{PC}} \right) + \frac{\left[\pi - \left(\frac{2\pi \times SH_1}{T_{PC}} \right) + SH_2 \right]}{2} \right\} \quad (7)$$

$$REG = \frac{\left[(S_2 - S_1)^2 - (S_2 - S_1) \right]}{\sqrt{2 \times \sqrt{(S_2 - S_1)^2}}} \quad (8)$$

where S_1 denotes the first sine-wave function, S_2 denotes the second sine-wave function, SH_1 denotes time when the function remains in state 0 (h), SH_2 denotes the peak shift time from state 0 to 1, T_{PC} denotes duration of the parasite life cycle (fixed to 38.8 h), and REG denotes the square-wave function regulating parasite movement. SH_1 and SH_2 values used to generate each square-wave function (REG_1 to REG_3) for each parasite compartment were based on time windows corresponding to *P. falciparum* parasite stages (39). Details on how these functions were implemented in the model are shown in the supplemental material (NONMEM code).

In the semimechanistic growth model, the parasite number in P1 was initialized with 1,800 parasites according to the approximate number of viable inoculated parasites. The parasites in P1 mature over time and started moving to P2 at 9.7 to 19.4 h (REG_1), and at 19.4 h, the entire parasite population in P1 moved to P2. The parasites in P2 continued to mature to schizonts, and either stayed in P2 or cytoadhered to the vascular endothelium and moved to P3 (sequestration). The sequestration of parasites was regulated (REG_2) to occur during the latter half of the parasite life cycle at 19.4 to 38.8 h since sequestration begins at the large ring stage (40, 41). At the end of the parasite life cycle (38.8 h), the matured schizonts in P2 and P3 ruptured and released new merozoites back to compartment P1 (REG_3). The PMR_{LC} associated with the rupture of schizonts was estimated. This semimechanistic growth model was described by the following differential equations system (equation 9 to 11).

$$\frac{dP1}{dt} = -P1 \times k_{MAT} \times REG_1 + (P2 + P3) \times k_{RUP} \times REG_3 \times PMR_{LC} \quad (9)$$

$$\frac{dP2}{dt} = P1 \times k_{MAT} \times REG_1 - P2 \times k_{SQ} \times REG_2 - P2 \times k_{RUP} \times REG_3 \quad (10)$$

$$\frac{dP3}{dt} = P2 \times k_{SQ} \times REG_2 - P3 \times k_{RUP} \times REG_3 \quad (11)$$

where k_{MAT} denotes the first-order rate constant for small rings to become mature parasites; k_{SQ} denotes the first-order rate constant for parasite sequestration; k_{RUP} denotes the first-order rate constant of schizont rupture; and REG_1 , REG_2 , and REG_3 denote the square-wave functions regulating the time and duration of parasite movement in each parasite compartment. Details of the square-wave functions used to regulate parasite movement are presented in the Fig. 4. In order to describe the parasite sequestration in a quantitative manner, the parasite sequestration rate was parameterized as a fraction of sequestered parasites (equation 12).

$$k_{SQ} = \frac{\ln \left[\frac{100}{(100 - F_{SQ})} \right]}{T_{PC} - (T_{SQ})} \quad (12)$$

where F_{SQ} denotes the fraction of sequestered parasite (%) and T_{SQ} denotes the onset of parasite sequestration (restricted to be between 19.4 and 38.8 h).

In vivo parasitocidal effect of piperaquine. The model that best described the parasite growth dynamics was carried forward and linked to the pharmacokinetic model of piperaquine. The final parameter estimates from the best performing model was used to impute individual growth time profiles. All total circulating parasite data, including the total circulating parasites after piperaquine administration, were used to estimate the parameters associated with the drug-dependent parasite elimination (Fig. S6). The parasitocidal effect of piperaquine was implemented as an E_{max} function (equation 13).

$$EFF = \left(E_{\max} \times \frac{C_p^\gamma}{C_p^\gamma + EC_{50}^\gamma} \right) \quad (13)$$

where EFF denotes the parasitocidal effect of piperazine (h^{-1}), E_{\max} denotes the maximum parasite killing rate of piperazine (h^{-1}), C_p denotes piperazine plasma concentration (ng/ml), EC_{50} denotes the plasma concentration of piperazine (ng/ml) associated with half of maximum parasite killing rate, and γ denotes the hill factor. Piperazine was assumed to have an effect on the later stages of blood-stage parasites (P2 and P3 compartment) based on previously published information (21, 22). The implementation of the drug effect was described by the following differential equations (equations 14 and 15). Cure was assumed to be achieved when the total parasite biomass (P1 + P2 + P3) was less than 1 parasite, triggering the PMR_{LC} to be 1 (i.e., resulting in no parasite growth).

$$\frac{dP2}{dt} = P1 \times k_{MAT} \times REG_1 - P2 \times k_{SQ} \times REG_2 - P2 \times k_{RUP} \times REG_3 - P2 \times EFF \quad (14)$$

$$\frac{dP3}{dt} = P2 \times k_{SQ} \times REG_2 - P3 \times k_{RUP} \times REG_3 - P3 \times EFF \quad (15)$$

The simulation-based diagnostics (i.e., visual predictive checks) of the final pharmacokinetic-pharmacodynamic model was based on 1,000 simulations using the individual parameter estimates from the final pharmacokinetic model and the final parameter estimates from the pharmacokinetic-pharmacodynamic model. Frequent dummy time points were added to the data set for simulations (every 5 h, from 0 h to 576 h). The visual predictive checks were stratified on the day of piperazine treatment and the predicted treatment outcome (curative versus recrudescence infection). The observed data were overlaid with the 90% prediction interval from 1,000 simulations to evaluate the predictive performance of the model.

Clinical scenario simulations. The final pharmacokinetic-pharmacodynamic model describing the dynamic parasite growth and piperazine *in vivo* parasitocidal effects was used to perform population-based simulations of clinical scenarios in NONMEM. Simulations were performed to predict the probability of treatment failure at different levels of drug resistance. The total number of circulating parasites was initialized with 10^6 or 10^{10} parasites in order to simulate asymptomatic and symptomatic infections, respectively. The following six different clinical scenarios with resistant infections were simulated to predict the probability of treatment failure: (1) absence of artemisinin resistance and absence of piperazine resistance, (2) presence of artemisinin resistance and absence of piperazine resistance, (3) absence of artemisinin resistance and presence of piperazine resistance ($2 \times EC_{50}$ of piperazine), and (4) to (6) presence of artemisinin resistance and presence of piperazine resistance ($2 \times EC_{50}$, $3 \times EC_{50}$, and $4 \times EC_{50}$ of piperazine).

Dihydroartemisinin was used as a representative of the artemisinin derivative, and pharmacokinetic parameters of dihydroartemisinin were taken from a previously published population pharmacokinetic analysis (42). The parasitocidal effect of dihydroartemisinin was adjusted based on the observed parasite clearance half-life from the Tracking Resistance to Artemisinin Collaboration (TRAC) study data (28). The reported mean parasite clearance half-life for sensitive (2.5 h) and resistant (6.2 h) infections from the TRAC study was used to calculate the parasite clearance slope and generate parasite clearance profiles, starting at an initial total circulating parasite density of 10^{11} parasites (Fig. S5). Simulations were performed in Berkeley Madonna (43) using the developed semimechanistic growth model to adjust the E_{\max} values of dihydroartemisinin to match the parasite clearance profiles generated from the parasite clearance half-life reported in the TRAC study. The derived adjusted E_{\max} values, resulting in equivalent residual total circulating parasites at 72 h as seen in the TRAC study, were used throughout the simulations.

The parasite killing effect of dihydroartemisinin was implemented in all parasite compartments (P1, P2, and P3) using an E_{\max} function (equation 13) because dihydroartemisinin has an effect on almost all stages of the parasite life cycle (44). Treatment failure was defined as a predicted total parasite biomass of >1 parasites at 30 days after the first dose of piperazine was given. Additionally, simulations were conducted to predict the probability of treatment failure when adding an additional hypothetical drug to the conventional dihydroartemisinin-piperazine regimen. The effect of the hypothetical drug was implemented in the same manner as the parasite killing effect of piperazine (added on P2 and P3 compartments). Different efficacy and duration of action of the hypothetical drug were investigated, including drugs demonstrating a PRR_{LC} of 10^1 , 10^2 , and 10^3 and a duration of action of 1 week, 2 weeks, 3 weeks, 4 weeks, and 5 weeks. The following differential equations described the drug effects for the simulations (equation 16 to 18)

$$\frac{dP1}{dt} = -P1 \times k_{MAT} \times REG_1 + (P2 + P3) \times k_{RUP} \times REG_3 \times PMR_{LC} - P1 \times EFF_1 \quad (16)$$

$$\frac{dP2}{dt} = P1 \times k_{MAT} \times REG_1 - P2 \times k_{SQ} \times REG_2 - P2 \times k_{RUP} \times REG_3 - P2 \times EFF_1 - P2 \times EFF_2 - P2 \times EFF_3 \quad (17)$$

$$\frac{dP_3}{dt} = P_2 \times k_{SQ} \times \text{REG}_2 - P_3 \times k_{RUP} \times \text{REG}_3 - P_3 \times \text{EFF}_1 - P_3 \times \text{EFF}_2 - P_3 \times \text{EFF}_3 \quad (18)$$

where EFF_1 denotes the parasitocidal effect of dihydroartemisinin, EFF_2 denotes the parasitocidal effect of piperaquine, and EFF_3 denotes the parasitocidal effect of the third hypothetical drug.

Each simulation scenario consisted of 4,800 simulated patients, including 48 individuals with various times of first dose with a 1-h difference among each simulated patient from 0 to 48 h (100 simulations). The variation mimics a real-life scenario where patients present to the clinic and receive treatment at different stages of the parasite life cycle. The standard 3-day dose of dihydroartemisinin-piperaquine (120/960 mg) for a patient weighing 60 kg was used in all simulations. A schematic illustration of the structural model used for simulations is presented in the supplemental material (Fig. S7).

SUPPLEMENTAL MATERIAL

Supplemental material is available online only.

SUPPLEMENTAL FILE 1, PDF file, 2.5 MB.

ACKNOWLEDGMENTS

We thank the volunteers who consented to participate in this study.

This work was supported by the Wellcome Trust (220211), Medicines for Malaria Venture, and the Bill & Melinda Gates Foundation (INV-006052, OPP1134284).

REFERENCES

- World Health Organization. 2018. World malaria report 2018. World Health Organization, Geneva, Switzerland.
- Dondorp AM, Nosten F, Yi P, Das D, Phyo AP, Tarning J, Lwin KM, Arie F, Hanpithakpong W, Lee SJ, Ringwald P, Silamut K, Imwong M, Chotivanich K, Lim P, Herdman T, An SS, Yeung S, Singhasivanon P, Day NP, Lindegardh N, Socheat D, White NJ. 2009. Artemisinin resistance in *Plasmodium falciparum* malaria. *N Engl J Med* 361:455–467. <https://doi.org/10.1056/NEJMoa0808859>.
- Phyo AP, Nkhoma S, Stepniwsky K, Ashley EA, Nair S, McGready R, Ler Moo C, Al-Saai S, Dondorp AM, Lwin KM, Singhasivanon P, Day NP, White NJ, Anderson TJ, Nosten F. 2012. Emergence of artemisinin-resistant malaria on the western border of Thailand: a longitudinal study. *Lancet* 379:1960–1966. [https://doi.org/10.1016/S0140-6736\(12\)60484-X](https://doi.org/10.1016/S0140-6736(12)60484-X).
- Amaratunga C, Lim P, Suon S, Sreng S, Mao S, Sopha C, Sam B, Dek D, Try V, Amato R, Blessborn D, Song L, Tullo GS, Fay MP, Anderson JM, Tarning J, Fairhurst RM. 2016. Dihydroartemisinin-piperaquine resistance in *Plasmodium falciparum* malaria in Cambodia: a multisite prospective cohort study. *Lancet Infect Dis* 16:357–365. [https://doi.org/10.1016/S1473-3099\(15\)00487-9](https://doi.org/10.1016/S1473-3099(15)00487-9).
- Amato R, Lim P, Miotto O, Amaratunga C, Dek D, Pearson RD, Almago-Garcia J, Neal AT, Sreng S, Suon S, Drury E, Jyothi D, Stalker J, Kwiatkowski DP, Fairhurst RM. 2017. Genetic markers associated with dihydroartemisinin-piperaquine failure in *Plasmodium falciparum* malaria in Cambodia: a genotype-phenotype association study. *Lancet Infect Dis* 17:164–173. [https://doi.org/10.1016/S1473-3099\(16\)30409-1](https://doi.org/10.1016/S1473-3099(16)30409-1).
- van der Pluijm RW, Tripura R, Hoglund RM, Pyae Phyo A, Lek D, Ul Islam A, Anvikar AR, Satpathi P, Satpathi S, Behera PK, Tripura A, Baidya S, Onyamboko M, Chau NH, Sovann Y, Suon S, Sreng S, Mao S, Oun S, Yen S, Amaratunga C, Chutasmit K, Saelow C, Runchareon R, Kaewmook W, Hoa NT, Thanh NV, Hanboonkunupakarn B, Callery JJ, Mohanty AK, Heaton J, Thant M, Gantait K, Ghosh T, Amato R, Pearson RD, Jacob CG, Gonçalves S, Mukaka M, Waithira N, Woodrow CJ, Grobusch MP, van Vugt M, Fairhurst RM, Cheah PY, Peto TJ, von Seidlein L, Dhorda M, Maude RJ, Winterberg M, et al. 2020. Triple artemisinin-based combination therapies versus artemisinin-based combination therapies for uncomplicated *Plasmodium falciparum* malaria: a multicentre, open-label, randomised clinical trial. *Lancet* 395:1345–1360. [https://doi.org/10.1016/S0140-6736\(20\)30552-3](https://doi.org/10.1016/S0140-6736(20)30552-3).
- Macintyre F, Adoke Y, Tiono AB, Duong TT, Mombo-Ngoma G, Bouyou-Akoté M, Tinto H, Bassat Q, Issifou S, Adamy M, Demarest H, Duparc S, Leroy D, Laurijsens BE, Biquenet S, Kibuuka A, Tshetu AK, Smith M, Foster C, Leipoldt I, Kremsner PG, Phuc BQ, Ouedraogo A, Ramharther M, OZ-Piperaquine Study Group. 2017. A randomised, double-blind clinical phase II trial of the efficacy, safety, tolerability and pharmacokinetics of a single dose combination treatment with artefenomel and piperaquine in adults and children with uncomplicated *Plasmodium falciparum* malaria. *BMC Med* 15:181. <https://doi.org/10.1186/s12916-017-0940-3>.
- Tarning J, Rijken MJ, McGready R, Phyo AP, Hanpithakpong W, Day NP, White NJ, Nosten F, Lindegardh N. 2012. Population pharmacokinetics of dihydroartemisinin and piperaquine in pregnant and nonpregnant women with uncomplicated malaria. *Antimicrob Agents Chemother* 56:1997–2007. <https://doi.org/10.1128/AAC.05756-11>.
- Hoglund RM, Adam I, Hanpithakpong W, Ashton M, Lindegardh N, Day NP, White NJ, Nosten F, Tarning J. 2012. A population pharmacokinetic model of piperaquine in pregnant and non-pregnant women with uncomplicated *Plasmodium falciparum* malaria in Sudan. *Malar J* 11:398. <https://doi.org/10.1186/1475-2875-11-398>.
- Tarning J, Zongo I, Some FA, Rouamba N, Parikh S, Rosenthal PJ, Hanpithakpong W, Jongrak N, Day NP, White NJ, Nosten F, Ouedraogo JB, Lindegardh N. 2012. Population pharmacokinetics and pharmacodynamics of piperaquine in children with uncomplicated falciparum malaria. *Clin Pharmacol Ther* 91:497–505. <https://doi.org/10.1038/clpt.2011.254>.
- Hoglund RM, Workman L, Edstein MD, Thanh NX, Quang NN, Zongo I, Ouedraogo JB, Borrmann S, Mwai L, Nsanzabana C, Price RN, Dahal P, Sambol NC, Parikh S, Nosten F, Ashley EA, Phyo AP, Lwin KM, McGready R, Day NP, Guerin PJ, White NJ, Barnes KI, Tarning J. 2017. Population pharmacokinetic properties of piperaquine in falciparum malaria: an individual participant data meta-analysis. *PLoS Med* 14:e1002212. <https://doi.org/10.1371/journal.pmed.1002212>.
- Liu H, Zhou H, Cai T, Yang A, Zang M, Xing J. 2018. Metabolism of piperaquine to its antiparasmodial metabolites and their pharmacokinetic profiles in healthy volunteers. *Antimicrob Agents Chemother* 62:e00260-18. <https://doi.org/10.1128/AAC.00260-18>.
- Nguyen DV, Nguyen QP, Nguyen ND, Le TT, Nguyen TD, Dinh DN, Nguyen TX, Bui D, Chavchich M, Edstein MD. 2009. Pharmacokinetics and ex vivo pharmacodynamic antimalarial activity of dihydroartemisinin-piperaquine in patients with uncomplicated falciparum malaria in Vietnam. *Antimicrob Agents Chemother* 53:3534–3537. <https://doi.org/10.1128/AAC.01717-08>.
- Tarning J, Thana P, Phyo AP, Lwin KM, Hanpithakpong W, Ashley EA, Day NP, Nosten F, White NJ. 2014. Population pharmacokinetics and antimalarial pharmacodynamics of piperaquine in patients with *Plasmodium vivax* malaria in Thailand. *CPT Pharmacometrics Syst Pharmacol* 3:e132. <https://doi.org/10.1038/psp.2014.29>.
- Chotsiri P, Zongo I, Milligan P, Compaore YD, Some AF, Chandramohan D, Hanpithakpong W, Nosten F, Greenwood B, Rosenthal PJ, White NJ, Ouedraogo JB, Tarning J. 2019. Optimal dosing of dihydroartemisinin-piperaquine for seasonal malaria chemoprevention in young children. *Nat Commun* 10:480. <https://doi.org/10.1038/s41467-019-08297-9>.
- McCarthy JS, Sekuloski S, Griffin PM, Elliott S, Douglas N, Peatey C, Rockett R, O'Rourke P, Marquart L, Hermesen C, Duparc S, Mohrle J, Trenholme KR, Humberstone AJ. 2011. A pilot randomised trial of induced blood-stage *Plasmodium falciparum* infections in healthy volunteers for testing efficacy of new antimalarial drugs. *PLoS One* 6:e21914. <https://doi.org/10.1371/journal.pone.0021914>.
- Wockner LF, Hoffmann I, Webb L, Mordmüller B, Murphy SC, Kublin JG, O'Rourke P, McCarthy JS, Marquart L. 2019. Growth rate of *Plasmodium*

- falciparum: analysis of parasite growth data from malaria volunteer infection studies. *J Infect Dis* 221:963–972. <https://doi.org/10.1093/infdis/jiz557>.
18. Delves M, Plouffe D, Scheurer C, Meister S, Wittlin S, Winzeler EA, Sinden RE, Leroy D. 2012. The activities of current antimalarial drugs on the life cycle stages of *Plasmodium*: a comparative study with human and rodent parasites. *PLoS Med* 9:e1001169. <https://doi.org/10.1371/journal.pmed.1001169>.
 19. Chotivanich K, Udomsangpetch R, Simpson JA, Newton P, Pukrittayakamee S, Looareesuwan S, White NJ. 2000. Parasite multiplication potential and the severity of *Falciparum* malaria. *J Infect Dis* 181:1206–1209. <https://doi.org/10.1086/315353>.
 20. Simpson JA, Aarons L, Collins WE, Jeffery GM, White NJ. 2002. Population dynamics of untreated *Plasmodium falciparum* malaria within the adult human host during the expansion phase of the infection. *Parasitology* 124:247–263. <https://doi.org/10.1017/s0031182001001202>.
 21. Wilson DW, Langer C, Goodman CD, McFadden GI, Beeson JG. 2013. Defining the timing of action of antimalarial drugs against *Plasmodium falciparum*. *Antimicrob Agents Chemother* 57:1455–1467. <https://doi.org/10.1128/AAC.01881-12>.
 22. Patel K, Batty KT, Moore BR, Gibbons PL, Kirkpatrick CM. 2014. Predicting the parasite killing effect of artemisinin combination therapy in a murine malaria model. *J Antimicrob Chemother* 69:2155–2163. <https://doi.org/10.1093/jac/dku120>.
 23. Ross LS, Dhingra SK, Mok S, Yeo T, Wicht KJ, Kumpornsin K, Takala-Harrison S, Witkowski B, Fairhurst RM, Arief F, Menard D, Fidock DA. 2018. Emerging Southeast Asian PfCRT mutations confer *Plasmodium falciparum* resistance to the first-line antimalarial piperazine. *Nat Commun* 9:3314. <https://doi.org/10.1038/s41467-018-05652-0>.
 24. Agarwal P, Anvikar AR, Pillai CR, Srivastava K. 2017. In vitro susceptibility of Indian *Plasmodium falciparum* isolates to different antimalarial drugs & antibiotics. *Indian J Med Res* 146:622–628. https://doi.org/10.4103/ijmr.IJMR_1688_15.
 25. Stanisic DI, Liu XQ, De SL, Batzloff MR, Forbes T, Davis CB, Sekuloski S, Chavchich M, Chung W, Trenholme K, McCarthy JS, Li T, Sim BK, Hoffman SL, Good MF. 2015. Development of cultured *Plasmodium falciparum* blood-stage malaria cell banks for early phase in vivo clinical trial assessment of anti-malaria drugs and vaccines. *Malar J* 14:143. <https://doi.org/10.1186/s12936-015-0663-x>.
 26. Pasay CJ, Rockett R, Sekuloski S, Griffin P, Marquart L, Peatey C, Wang CY, O'Rourke P, Elliott S, Baker M, Mohrle JJ, McCarthy JS. 2016. Piperazine monotherapy of drug-susceptible *Plasmodium falciparum* infection results in rapid clearance of parasitemia but is followed by the appearance of gametocytemia. *J Infect Dis* 214:105–113. <https://doi.org/10.1093/infdis/jiw128>.
 27. White NJ. 1997. Assessment of the pharmacodynamic properties of antimalarial drugs in vivo. *Antimicrob Agents Chemother* 41:1413–1422. <https://doi.org/10.1128/AAC.41.7.1413>.
 28. Ashley EA, Dhorda M, Fairhurst RM, Amaratunga C, Lim P, Suon S, Sreng S, Anderson JM, Mao S, Sam B, Sopha C, Chuor CM, Nguon C, Sovannaroeth S, Pukrittayakamee S, Jittamala P, Chotivanich K, Chutasmit K, Suchatsoonthorn C, Runchaoen R, Hien TT, Thuy-Nhien NT, Thanh NV, Phu NH, Htut Y, Han KT, Aye KH, Mokuolu OA, Olaosebikan RR, Folaranmi OO, Mayxay M, Khanthavong M, Hongvanthong B, Newton PN, Onyamboko MA, Fanello CI, Tshetu AK, Mishra N, Valecha N, Phyo AP, Nosten F, Yi P, Tripura R, Borrmann S, Bashraheil M, Peshu J, Faiz MA, Ghose A, Hossain MA, Samad R, Tracking Resistance to Artemisinin Collaboration (TRAC), et al. 2014. Spread of artemisinin resistance in *Plasmodium falciparum* malaria. *N Engl J Med* 371:411–423. <https://doi.org/10.1056/NEJMoa1314981>.
 29. Dini S, Zaloumis S, Cao P, Price RN, Fowkes FJL, van der Pluijm RW, McCaw JM, Simpson JA. 2018. Investigating the efficacy of triple artemisinin-based combination therapies for treating *Plasmodium falciparum* malaria patients using mathematical modeling. *Antimicrob Agents Chemother* 62:e01068-18. <https://doi.org/10.1128/AAC.01068-18>.
 30. Marquart L, Baker M, O'Rourke P, McCarthy JS. 2015. Evaluating the pharmacodynamic effect of antimalarial drugs in clinical trials by quantitative PCR. *Antimicrob Agents Chemother* 59:4249–4259. <https://doi.org/10.1128/AAC.04942-14>.
 31. RStudio Team. 2018. RStudio: integrated development for R. RStudio, Inc., Boston, MA <http://www.rstudio.com/>.
 32. Keizer RJ, van Benten M, Beijnen JH, Schellens JH, Huitema AD. 2011. Pirana and PCluster: a modeling environment and cluster infrastructure for NONMEM. *Comput Methods Programs Biomed* 101:72–79. <https://doi.org/10.1016/j.cmpb.2010.04.018>.
 33. Lindbom L, Ribbing J, Jonsson EN. 2004. Perl-speaks-NONMEM (PsN)—a Perl module for NONMEM related programming. *Comput Methods Programs Biomed* 75:85–94. <https://doi.org/10.1016/j.cmpb.2003.11.003>.
 34. Beal SL. 2001. Ways to fit a PK model with some data below the quantification limit. *J Pharmacokinet Pharmacodyn* 28:481–504. <https://doi.org/10.1023/A:1012299115260>.
 35. Bergstrand M, Karlsson MO. 2009. Handling data below the limit of quantification in mixed effect models. *AAPS J* 11:371–380. <https://doi.org/10.1208/s12248-009-9112-5>.
 36. Mould DR, Upton RN. 2013. Basic concepts in population modeling, simulation, and model-based drug development-part 2: introduction to pharmacokinetic modeling methods. *CPT Pharmacometrics Syst Pharmacol* 2:e38. <https://doi.org/10.1038/psp.2013.14>.
 37. Savic RM, Karlsson MO. 2009. Importance of shrinkage in empirical bayes estimates for diagnostics: problems and solutions. *AAPS J* 11:558–569. <https://doi.org/10.1208/s12248-009-9133-0>.
 38. Dondorp AM, Desakorn V, Pongtavornpinyo W, Sahassananda D, Silamut K, Chotivanich K, Newton PN, Pitisuttithum P, Smithyman AM, White NJ, Day NP. 2005. Estimation of the total parasite biomass in acute *falciparum* malaria from plasma PfHRP2. *PLoS Med* 2:e204. <https://doi.org/10.1371/journal.pmed.0020204>.
 39. Silamut K, Phu NH, Whitty C, Turner GD, Louwrier K, Mai NT, Simpson JA, Hien TT, White NJ. 1999. A quantitative analysis of the microvascular sequestration of malaria parasites in the human brain. *Am J Pathol* 155:395–410. [https://doi.org/10.1016/S0002-9440\(10\)65136-X](https://doi.org/10.1016/S0002-9440(10)65136-X).
 40. White NJ. 2011. The parasite clearance curve. *Malar J* 10:278. <https://doi.org/10.1186/1475-2875-10-278>.
 41. Udomsangpetch R, Pipitaporn B, Silamut K, Pinches R, Kyes S, Looareesuwan S, Newbold C, White NJ. 2002. Febrile temperatures induce cytoadherence of ring-stage *Plasmodium falciparum*-infected erythrocytes. *Proc Natl Acad Sci U S A* 99:11825–11829. <https://doi.org/10.1073/pnas.172398999>.
 42. Chotsiri P, Wattanakul T, Hoglund R, Hanboonkunupakarn B, Pukrittayakamee S, Blessborn D, Jittamala P, White NJ, Day NPJ, Tarning J. 2017. Population pharmacokinetics and electrocardiographic effects of dihydroartemisinin-piperazine in healthy volunteers. *Br J Clin Pharmacol* 83:2752–2766. <https://doi.org/10.1111/bcp.13372>.
 43. Macey R, Oster G, Zahley T. 2000. Berkeley Madonna; Berkeley, CA. <http://berkeleymadonna.com>.
 44. ter Kuile F, White NJ, Holloway P, Pasvol G, Krishna S. 1993. *Plasmodium falciparum*: in vitro studies of the pharmacodynamic properties of drugs used for the treatment of severe malaria. *Exp Parasitol* 76:85–95. <https://doi.org/10.1006/expr.1993.1010>.